MAP2K7 and neoplasm: Anti-tumor activity of sorafenib mainly involves inhibition of tumor cell proliferation and angiogenesis by blocking the RAF/MEK/ERK pathway (6, 7), and sorafenib was expected to reduce postoperative HCC recurrence that resulted from growth of unrecognized residual tumor cells or circulating tumor cells.